Universitätspublikationen
Refine
Year of publication
- 2017 (1982) (remove)
Document Type
- Article (897)
- Part of Periodical (210)
- Doctoral Thesis (178)
- Contribution to a Periodical (147)
- Working Paper (118)
- Report (110)
- Review (103)
- Book (93)
- Preprint (64)
- Part of a Book (17)
Language
- English (1200)
- German (734)
- Portuguese (22)
- Spanish (11)
- Multiple languages (6)
- French (4)
- Ukrainian (2)
- Catalan (1)
- Italian (1)
- Turkish (1)
Is part of the Bibliography
- no (1982)
Keywords
- Financial Institutions (41)
- Banking Supervision (22)
- Banking Resolution (20)
- BRRD (19)
- Banking Regulation (18)
- Alte Geschichte (16)
- Household Finance (15)
- SSM (15)
- Bail-in (14)
- Banking Union (14)
Institute
- Medizin (381)
- Präsidium (285)
- Physik (236)
- Wirtschaftswissenschaften (209)
- Gesellschaftswissenschaften (195)
- Sustainable Architecture for Finance in Europe (SAFE) (163)
- Frankfurt Institute for Advanced Studies (FIAS) (115)
- Neuere Philologien (104)
- Biowissenschaften (103)
- Informatik (91)
Background: HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12.
Methods: This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simeprevir plus PR in 67 patients with HCV GT4 infection. Patients were treatment-naïve, aged 18–70 years with METAVIR F0–F2 fibrosis. Patients with early virologic response (HCV RNA <25 IU/mL [detectable/undetectable in IL28B CC patients or undetectable in IL28B CT/TT patients] at Week 2 and undetectable at Weeks 4 and 8) were eligible to stop all treatment at the end of Week 12, otherwise PR therapy was continued to Week 24.
Results: Of 67 patients treated, 34 (51%) qualified for 12-week treatment including all but one patient with IL28B CC genotype (14/15). All patients in the 12-week group had undetectable HCV RNA at end of treatment, and 97% (33/34) achieved SVR12. No new safety signals with simeprevir plus PR were identified. The proportion of patients experiencing Grade 3–4 adverse events was lower in the 12-week group than in the 24-week group.
Conclusions: Our findings on simeprevir plus PR therapy shortened to 12 weeks in patients with HCV GT4 infection with favourable baseline characteristics and displaying early on-treatment virologic response are encouraging. No new safety signals were associated with simeprevir plus PR in this study.
The oncogene B-cell lymphoma 6 (BCL6) is associated with lymphomagenesis. Intriguingly, its expression is increased in preeclamptic placentas. Preeclampsia is one of the leading causes of maternal and perinatal mortality and morbidity. Preeclamptic placentas are characterized by various defects like deregulated differentiation and impaired fusion of trophoblasts. Its pathogenesis is however not totally understood. We show here that BCL6 is present throughout the cell fusion process in the fusogenic trophoblastic cell line BeWo. Suppression of BCL6 promotes trophoblast fusion, indicated by enhanced levels of fusion-related β-hCG, syncytin 1 and syncytin 2. Increased mRNA levels of these genes could also be observed in primary term cytotrophoblasts depleted of BCL6. Conversely, stable overexpression of BCL6 reduces the fusion capacity of BeWo cells. These data suggest that an accurately regulated expression of BCL6 is important for proper differentiation and successful syncytialization of trophoblasts. While deregulated BCL6 is linked to lymphomagenesis by blocking lymphocyte terminal differentiation, increased BCL6 in the placenta contributes to the development of preeclampsia by impairing trophoblast differentiation and fusion.